Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 20.75
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010,...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell